Acumen updates INTERCEPT-AD trial enrollment, dose reduction for Cohort 7

Acumen Pharmaceuticals, Inc.

Expects enrollment completion Q1 2023, topline data Q3 2023.
52 subjects randomized and dosed in Cohorts 1-6 as of Jan 31, 2023.
Submitted protocol amendment Jan 30, 2023: Cohort 7 reduced to 25 mg/kg every 2 weeks from 60 mg/kg.
Two asymptomatic ARIA-E cases: one in Cohort 4 (single 60 mg/kg), one in Cohort 5 (third 10 mg/kg).
Dose reduction based on blinded PK/PD data; 60 mg/kg every 2 weeks deemed unnecessary for target engagement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.